Animal data suggest that ticagrelor but not clopidogrel protects against tissue injury. It is unclear if this effect of ticagrelor is also detectable in humans. We studied the effect of ticagrelor and clopidogrel at standard clinical doses on endothelial dysfunction in an experimental model of forearm vascular ischaemia-reperfusion (IR) injury.
Introduction
Rapid reperfusion of ischaemic tissue is essential to prevent cell death. However, reperfusion itself has a deleterious effect on tissue function leading to paradoxical ischaemiareperfusion (IR) injury [1, 2] . This is partly attributed to accumulation of reactive oxygen species (ROS) that emerge during reperfusion due to the incapacity of physiologic cellular antioxidant mechanisms [3] [4] [5] . The endothelium has also been shown to be vulnerable to IR injury with markedly suppressed endothelial nitric oxide (NO) synthase activity during reperfusion, and combined with increased ROS, leading to excessive inactivation of endothelial-derived NO [6, 7] . This may affect blood vessel function and consequently augment tissue injury. Beside endothelial dysfunction and enhanced ROS levels, IR also induces a local inflammatory response resulting in platelet activation [8] [9] [10] . Stimulated thrombocytes themselves have been considered to be important sources of ROS and thus may profoundly contribute to increased oxidative stress [11] . Various antiplatelet agents such as the glycoprotein IIb/IIIa inhibitor tirofiban or the platelet P2Y 12 receptor antagonist clopidogrel are known to exert beneficial effects on endothelial function in populations at risk for cardiovascular events [12, 13] .
Platelet inhibition with a P2Y 12 receptor antagonist such as clopidogrel, prasugrel or ticagrelor in combination with acetylsalicylic acid (ASA) has become a mainstay for the treatment of patients with an acute coronary syndrome (ACS) [14, 15] . In patients with ACS, ticagrelor has been shown to lower the risk of future cardiac events as compared to clopidogrel [16, 17] , which might not only be explained by clopidogrel's delayed onset of action or substantial inter-individual variability but may be due partly to ticagrelor's pleiotropic effects [18] [19] [20] . Preclinical animal data has recently suggested that ticagrelor but not clopidogrel has protective effects on IR injury by inhibition of cellular adenosine uptake with downstream NO-synthase stimulation [21] . It is unclear if this action is part of the superior clinical effect of ticagrelor in humans.
This trial aimed to investigate whether treatment with ticagrelor in healthy subjects can mitigate the transient loss of endothelium-dependent vasodilation of the vasculature following a short period of local ischaemia compared with clopidogrel at standard clinical doses for ACS. These pharmacodynamic effects were assessed after a loading dose and after 2 weeks of regular intake using a previously described model of ischaemia-induced endothelial dysfunction of the forearm resistance vasculature [22, 23] . This experimental approach was employed, as it is difficult to perform studies investigating IR injury in patients with acute ischaemia and evidence suggests that the endothelium-dependent vasomotor response of the forearm may serve as a surrogate for coronary endothelial function [24] .
Methods
The study protocol was approved by the Ethics Committee of the Medical University of Vienna, Austria (EK 1608/2015), and the national Competent Authority. It conforms to the principles outlined in the Declaration of Helsinki, including current revisions, and the ICH Good Clinical Practice Guidelines. The trial is registered at ClinicalTrials.gov (NCT02580149) and at the European Clinical Trials database (EudraCT 2015-002763-41). Written informed consent was obtained from all subjects before study enrolment.
Study population
Forty healthy, non-smoking male volunteers aged 18-40 with a body mass index (BMI) of 18-27 kg m À2 were evaluated for eligibility to randomize 24 subjects (Figure 1 ). Study participants were given a complete health examination at a screening visit and were excluded if they had any significant laboratory or physical finding; a history of cardiovascular disease, renal, hepatic or gastrointestinal impairment; an increased risk of bleeding or coagulation diseases; use of any medication within 2 weeks prior to inclusion. The screening visit was scheduled 3-21 days before the first study day. Subjects abstained from caffeine or xanthine-containing beverages 24 h before the study days and from alcohol during the period of drug intake.
Study design and study drugs
The trial followed a prospective, randomized, controlled, Figure 1 ). An end-of-study (EOS) visit was scheduled 1 week after the last treatment day.
Forearm blood flow measurements
Forearm blood flow (FBF) was assessed in both arms by strain gauge plethysmography as described previously [25, 26] . Briefly, strain gauges, placed on both forearms, were connected to plethysmographs (EC-6; D.E. Hokanson Inc., Bellevue, WA, USA) for measurement of changes in forearm volume in response to inflation of congesting cuffs on the upper arms to a supravenous pressure (45 mmHg). The distances from the elbows to the strain gauges were measured to ensure a comparable setting between study days. Measurements were recorded for 9 s at 30 s intervals during repeated inflation of the upper arm cuffs. The early linear increases of the curves were used for FBF analysis using the NIVP3 software (version 5.27, D.E. Hokanson Inc., Bellevue, WA, USA) and are expressed as ml* min À1 *100 ml À1 forearm volume.
Experimental protocol
After an overnight fast, FBF measurements were performed in a quiet room with an ambient constant temperature of 23°C (±1°C). FBF was assessed on Day 1 at pre-dose (prior to the loading dose) and on both study days before and after the non-dominant forearm was made ischaemic (Figure 2 ). Subjects were in a supine position and a 27 gauge finebore needle (Sol Care, Sol-Millennium Medical Inc., Lawrenceville, GA, USA) was inserted into the brachial artery of the non-dominant arm for intra-arterial administration of vasoactive agents. Control (0.9% sodium chloride solution; Fresenius Kabi, Graz, Austria) FBF measurements were recorded over 5 min followed by assessing the response to the endothelium-dependent vasodilator acetylcholine (ACh; Miochol-E ® , Bausch & Lomb Swiss AG, Switzerland) at increasing doses of 25, 50 and 100 nmol min À1 (each for 3 min), respectively. To test smooth muscle function, the endothelium-independent dilator glyceryltrinitrate (GTN; Nitro POHL, G. Pohl-Boskamp GmbH & Co. KG, Germany; 4, 8 and 16 nmol min À1 ; each for 3 min) was administered after a 15 min washout period to allow restoration of control FBF conditions. The intra-arterial needle was removed after pre-dose (i.e., before any study drug was administered on Day 1) and preischaemia FBF measurements. Forearm ischaemia was applied to the non-dominant arm 2 h after administration of ticagrelor or clopidogrel for 20 min by inflating an upper arm cuff to suprasystolic values (>220 mmHg). Immediately after cuff release, an intra-arterial cannula was reinserted followed by assessment of post-ischaemia FBF response starting at 10 min after reperfusion onset.
Platelet inhibition
Blood for assessment of platelet function was collected by fresh venepunctures on both study days at pre-dose (À2 h prior to ischaemia), immediately before (0 min) and after the 20 min forearm ischaemia, and at 70 min after forearm ischaemia ( Figure 2 ). To assess possible effects of local ischaemia on platelet function, blood samples during reperfusion were taken from both forearms. Blood was collected into tubes containing recombinant hirudin (Roche, Mannheim, Germany) and analysed within 0.5-3 h after sampling using multiple aggregometry (MEA; Multiplate ® Analyser; Roche). Three hundred millilitres of hirudin blood were diluted with 0.9% saline solution at a 1:1 ratio and Figure 1 Study flow diagram. LD, loading dose; bid, twice daily; qd, once daily Ischaemia-reperfusion injury and ticagrelor incubated for 3 min. After stirring at 37°C, analyses were performed with the agonist ADP and PGE 1 as inhibitor of platelet activation at final concentrations of 6.3 μM and 9.4 nM, respectively. The slope of the increase in electrical impedance was recorded for 6 min and is expressed as area under the curve (AUC) of the aggregation tracing [27, 28] . The normal reference range for the AUC is 43-100 units (U).
Study objectives
The predefined primary study endpoints were to compare the ratios of the area under the vasodilator dose vs. FBF curve (AUC) to ACh (ACh AUC ) post-vs. pre-ischaemia between treatment groups during acute and chronic administration of the medicines under study. Endothelium-dependent vasodilation was considered to be of primary interest since vasodilating smooth muscle function in the forearm vasculature has been shown to be unaffected by local ischaemia in a previous own trial [23] .
Secondary outcome parameters included GTN-induced vasodilation during reperfusion and assessment of additive effects of ticagrelor or clopidogrel on FBF reactivity in the absence of an ischaemic event (pre-ischaemia vs. pre-dose). Other secondary objectives were the inhibitory effect of ticagrelor and clopidogrel on whole blood platelet aggregation using MEA, and safety.
Statistical analysis and sample size estimation Redmond, WA, USA) were used for statistical analysis. All data were examined for normal distribution with the Kolomogorov-Smirnov test and log transformed for further analysis if they were non-normally distributed.
FBF was calculated as ml*min À1 *100 ml À1 forearm volume, percent changes, AUC or ratios before unblinding of the study. The effects of ACh or GTN (= mean of six measurements at each dose level) on FBF are expressed as percent changes of ratios from intervention vs. control forearm with individual basal FBF ratios (= mean of 10 measurements during saline infusion) defined as 100%. FBF-AUC were derived from the dose-effect curves according to the linear trapezoidal rule restricted to the range of active dosing consisting of three data points (i.e. 25, 50, 100 nmol*min À1 for ACh, and 4, 8, 16 nmol*min À1 for GTN, respectively). The effects of acute or chronic treatment with ticagrelor or clopidogrel on individual ACh or GTN dose levels and FBF-AUC during reperfusion (post-vs. preischaemia), a possible additive effect of the study medicines (pre-ischaemia vs. baseline [= before loading dose]), as well as the degree of platelet inhibition, were analysed by a repeated measures ANOVA. Time point and dose level were considered as within-subject factors, treatment as a between-group factor and, if appropriate, pre-dose (baseline) levels were used as covariate in the ANOVA model. Ratios of AUC were analysed using the two-sample t test and for the primary study objectives (ACh AUC ratios post-vs. preischaemia) the Bonferroni-Holm procedure was applied to adjust for multiple comparisons. All other (secondary) study objectives were analysed in an exploratory fashion. An Figure 2 Flow chart of the two study days that were 2 weeks apart. FBF, forearm blood flow; MEA, multiple electrode aggregometry (adjusted) two-sided P value <0.05 was considered to be statistically significant. Values are given as mean and 95% confidence interval (CI) unless indicated otherwise. Sample size calculation was based on the predefined primary outcome parameter ACh AUC ratio (post-vs. preischaemia). Previous data indicate that the within-group SD for the percent FBF changes at different ACh doses is approximately 20% [29] . Due to a lack of data for the expected impact of ticagrelor vs. clopidogrel on ACh-induced vasodilation, a difference of 25% between groups was considered to be clinically relevant. Thus, with a sample size of 12 subjects per group, a mean difference of 25% in the ACh AUC ratios (ticagrelor vs. clopidogrel) could be detected with 80% power using a two-sample t test at a significance level of 5% (two-sided). The calculated sample size of 12 per group included drop-out of one subject.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [30] , and are permanently archived in the Concise Guide to PHARMA-COLOGY 2015/16 [31] .
Results

Study population
Demographic and laboratory data of randomized study participants are presented in Table 1 .
Forearm blood flow
Basal FBF of the interventional and control arm during intraarterial saline infusion are presented in Table 2 . FBF at predose (before administration of ticagrelor or clopidogrel) on Day 1 was significantly higher in both the interventional and control arm as compared to the basal pre-or postischaemic FBF measurements (P = 0.005 [interventional arm] and P < 0.001 [non-interventional arm], ANOVA). However, FBF at corresponding time points was comparable between study cohorts and arms, respectively (P > 0.05 for group differences and interventional vs. control arm, ANOVA). Figure 3 shows the percent changes of ACh-induced vasodilation of the intervention vs. control arm (FBF ratio) at different dose levels and time points, respectively. ACh infusion caused a dose-dependent increase in FBF ratio on both study days (P < 0.001 for dose levels, ANOVA). FBF reactivity is summarized in Table 3 , and Figure 4 shows the FBF ratio calculated as ACh AUC at pre-dose and during acute or repeated dosing. There was a small increase in FBF reactivity after the loading dose and after multiple dosing of ticagrelor or clopidogrel, which was not statistically significant compared to baseline or between treatment groups (Table 3; Figure 4 ). At 10 min after reperfusion onset, FBF response was impaired and could not be completely normalized by ticagrelor or clopidogrel (P < 0.001 post-vs. pre-ischaemia ACh AUC Day 1 and Day 15, ANOVA). However, vasodilation to ACh was substantially less mitigated during ticagrelor loading as compared to clopidogrel (0.83 vs. 0.64 for ACh AUC ratios post-vs. pre-ischaemia; P = 0.024, twosample t test). After chronic administration, a similar response was observed on ACh AUC ratios with 0.86 during ticagrelor and 0.66 during clopidogrel intake, respectively (P = 0.027, two-sample t test). Differences in ACh AUC between groups resulted from a less impaired FBF reactivity at all ACh dose levels in subjects who received ticagrelor ( Figure 3 , C and E).
Endothelium-dependent (ACh-induced) response
Endothelium-independent (GTN-induced) response
The dose-dependent increases of endothelium-independent vasodilation were similar across study cohorts at all FBF assessments (P < 0.001 for dose levels, P = 0.75 for group differences, ANOVA). FBF ratios calculated from GTN AUC are presented in Table 3 . Administration of ticagrelor or clopidogrel did not significantly affect GTN-induced vasodilation and the response to GTN during reperfusion was similar to that seen prior to ischaemia after loading and after 2 weeks of regular intake of ticagrelor or clopidogrel.
Platelet inhibition
The impact of the medicines under study on MEA is summarized in Table 4 . Administration of ticagrelor or clopidogrel induced a rapid and sustained platelet inhibition, which was comparable between treatments (P < 0.001 vs. pre-dose, Table 1 Characteristics of study participants. Data are presented as mean and S.E.M. 
Figure 3
Forearm blood flow response to acetylcholine in the intervention vs. control arm (FBF ratio) at pre-dose (A), before a 20 min forearm ischaemia that was applied at 2 h after loading with ticagrelor or clopidogrel (B) and at 10 min of reperfusion (C). Panels D and E show the FBF response to acetylcholine after 14 days intake of ticagrelor or clopidogrel before (D) and at 10 min of reperfusion after forearm ischaemia. During reperfusion, reactivity to acetylcholine was less impaired in subjects receiving ticagrelor as compared to clopidogrel. FBF ratio is expressed as mean ± S.E.M.; n = 12 per group; *P < 0.05 for corresponding acetylcholine dose levels between groups; two-sample t test P = 0.41 for group differences, ANOVA). At 2 h after loading, (pre-ischaemia) reductions to 16 U (ticagrelor) and 22 U (clopidogrel) were noted. Platelet activation remained significantly attenuated during ticagrelor and clopidogrel (18 U) treatment after ischaemia, respectively. At pre-dose after 2 weeks of regular intake, the inhibitory effect was similar between ticagrelor and clopidogrel (20 U vs. 22 U) with maximum reductions to 16 U for ticagrelor or 14 U for clopidogrel after dosing. Forearm ischaemia on the interventional arm did not alter MEA responses as compared with the control arm (P > 0.05 interventional vs. control arm, paired t test; Table 4 ).
Safety
The medicines under study were well tolerated and the incidence of adverse events (AE) was low. Seventeen AEs were reported (ticagrelor: n = 10, clopidogrel: n = 7) that were mild in severity and resolved without sequelae. Six AEs were classified as probably related to antithrombotic treatment (haematoma [n = 1, ticagrelor; n = 3, clopidogrel], gingival bleeding [n = 1, ticagrelor], dyspnoea [n = 1, ticagrelor]), two AEs were caused by arterial needle insertion with transient paraesthesia and nine were considered to be unrelated to
Figure 4
Area under the vasodilator dose vs. forearm blood flow curve in the interventional vs. control arm to acetylcholine (ACh AUC ) at pre-dose (baseline) and after loading or multiple dose treatment with ticagrelor or clopidogrel over 14 days before and after ischaemia reperfusion (IR). (n = 12 per group). Data are presented as mean and 95% confidence interval; *P < 0.05 before vs. after IR; paired t test Table 3 Ratios of the area under the vasodilator dose vs. forearm blood flow curve to acetylcholine (ACh AUC ratio) or glyceryltrinitrate (GTN AUC ratio) at baseline (BL) before study drug administration and during treatment with ticagrelor or clopidogrel before (PRE) and after (POST) forearm ischaemia (n = 12 per group). Data are presented before and after acute dosing on Day 1 and after multiple dosing on Day 15 as mean and 95% confidence interval 
Discussion
This study demonstrates that IR-induced forearm vascular endothelial dysfunction could not be fully prevented by treatment with oral ticagrelor or clopidogrel at therapeutic doses. However, the transient loss of ACh-induced resistance to artery vasodilation was less impaired during ticagrelor compared with clopidogrel administration. After acute loading and after repeated dosing over 2 weeks, vasodilatory smooth muscle function was unaffected by IR. Both antiplatelet drugs induced a comparable and sustained platelet inhibition. These findings suggest that ticagrelor may have greater effects on resistance artery endothelial function than clopidogrel at an equivalent degree of platelet inhibition. Consistent with previous data, our results confirm that an intermittent arterial vascular occlusion causes severe endothelial dysfunction, whereas the endotheliumindependent vasodilator response is not markedly altered [23] . The present study employed an active control using clopidogrel as comparator and did not assess the impact of a transient ischaemia on the resistance forearm vasculature alone. A previous trial [23] in healthy participants demonstrated a similar vascular impairment during placebo administration as observed in our study with clopidogrel treatment, indicating that there is little if any effect of clopidogrel on ACh-induced vasodilation during reperfusion in healthy subjects. Further, the effect of prasugrel was not assessed in this study and it remains unclear whether this P2Y 12 receptor antagonist affects the endothelium-dependent FBF response. However, available data suggests that prasugrel does not improve vascular function substantially [32, 33] .
It has been proposed that ticagrelor's pleiotropic effects are mediated by locally increased adenosine concentrations and endothelial NO synthase activation that is considered, among others, to play a key role in preventing endothelial dysfunction and IR injury [16, 21, [34] [35] [36] . In our study orally administered ticagrelor at standard clinical doses could not fully restore ACh-stimulated vasodilation in the forearm vasculature. We cannot conclude if ticagrelor's limited benefit is due to exceeding its capacity of NO synthase stimulation with subsequent imbalance of NO and ROS as these parameter were not assessed. However, Campo et al. reported increased NO and mitigated ROS levels during ticagrelor treatment, which also induced higher adenosine plasma concentrations in cardiac patients [34, 37] .
Our data show that acute or chronic treatment with ticagrelor (or clopidogrel) had no effect on FBF reactivity in the absence of vascular ischaemia. It may be hypothesized that vascular NO bioactivity is not augmented by platelet inhibition, at least in healthy subjects under resting conditions. It is unlikely that the higher absolute FBF during saline infusion at pre-dose (Table 2) has affected this observation, as ratios of interventional vs. control arm were analysed and absolute changes of vasodilation in response to ACh did not differ between assessments (pre-ischaemia vs. pre-dose). The higher absolute baseline FBF prior to loading with the study medicines may be explained by a shorter resting period before the pre-dose FBF that was assessed shortly after admission to our department.
Pharmacodynamic responses obtained with MEA indicate that both ticagrelor and clopidogrel induced a comparable Post-ischaemia (+20 min) 18 (12; 24) and sustained platelet inhibition as noted in a previous healthy volunteer study [38] , which suggests that the observed group differences in FBF reactivity did not result from individual resistance to clopidogrel [27] . Mitigated vascular ACh reactivity resulting from a delayed onset of clopidogrel's action after loading can be ruled out as a similar ACh-induced vasodilation was observed at steady state after 2 weeks of regular intake. However, in at-risk populations, the response on platelet inhibition is more pronounced with ticagrelor compared to clopidogrel and it is possible that the clinically relevant differences in trials with ACS patients are related to the greater inhibitory properties of ticagrelor than to its pleiotropic effects [16, 39] . In patients with ACS, a P2Y 12 receptor antagonist in combination with acetylsalicylic acid (ASA) is recommended for secondary prevention and statin and angiotensinconverting enzyme (ACE) inhibitor therapy are prescribed [40] . Animal data has shown that the tissue protective effect of ticagrelor is not abrogated by co-administration of ASA (up to 5 mg kg À1 BW) [36] . In addition, statins and ACE inhibitors have also been suggested to ameliorate endothelial dysfunction and thus may modulate ticagrelor's effect in cardiac patients with co-medication [41] [42] [43] .
Limitations
The trial was conducted in healthy volunteers and an experimental vascular model of the forearm was used to assess IR injury. Thus it remains unclear whether our results can be extrapolated to a population at risk such as patients with ACS or peripheral artery disease with pre-existing endothelial dysfunction and acute ischaemia in a different vascular bed with thrombus formation. Further, the more potent P2Y 12 receptor antagonist prasugrel was not tested and markers of oxidative stress (ROS, NO) or adenosine concentrations were not assessed.
Conclusion
The impairment of ACh-induced vasodilation during reperfusion after acute vascular occlusion was less pronounced after ticagrelor administration compared to clopidogrel. This was detectable following a loading dose and after 2 weeks of regular intake of ticagrelor or clopidogrel, despite a similar degree of platelet inhibition achieved.
